BRPI0607827A2 - composto precursor de inibidor de protease, processo para produção do referido composto e seu uso - Google Patents

composto precursor de inibidor de protease, processo para produção do referido composto e seu uso

Info

Publication number
BRPI0607827A2
BRPI0607827A2 BRPI0607827-3A BRPI0607827A BRPI0607827A2 BR PI0607827 A2 BRPI0607827 A2 BR PI0607827A2 BR PI0607827 A BRPI0607827 A BR PI0607827A BR PI0607827 A2 BRPI0607827 A2 BR PI0607827A2
Authority
BR
Brazil
Prior art keywords
compound
protease
producing
inhibitor precursor
protease inhibitor
Prior art date
Application number
BRPI0607827-3A
Other languages
English (en)
Inventor
Bruno Linclau
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of BRPI0607827A2 publication Critical patent/BRPI0607827A2/pt
Publication of BRPI0607827B1 publication Critical patent/BRPI0607827B1/pt
Publication of BRPI0607827B8 publication Critical patent/BRPI0607827B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

COMPOSTO PRECURSOR DE INIBIDOR DE PROTEASE, PROCESSO PARA A PRODUçãO DO REFERIDO COMPOSTO E SEU USO. A presente invenção refere-se a um composto tendo a estrutura (I), e processos para a produção deste, e os intermediários usados em tal processo.
BRPI0607827A 2005-02-25 2006-02-24 composto precursor de inibidor de protease, processo para a produção do referido composto e seu uso BRPI0607827B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05101462 2005-02-25
US68369905P 2005-05-23 2005-05-23
PCT/EP2006/060246 WO2006089942A1 (en) 2005-02-25 2006-02-24 Protease inhibitor precursor synthesis

Publications (3)

Publication Number Publication Date
BRPI0607827A2 true BRPI0607827A2 (pt) 2009-10-06
BRPI0607827B1 BRPI0607827B1 (pt) 2019-11-05
BRPI0607827B8 BRPI0607827B8 (pt) 2021-05-25

Family

ID=36646227

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607827A BRPI0607827B8 (pt) 2005-02-25 2006-02-24 composto precursor de inibidor de protease, processo para a produção do referido composto e seu uso

Country Status (19)

Country Link
US (2) US8067463B2 (pt)
EP (1) EP1856125B1 (pt)
JP (1) JP5260965B2 (pt)
KR (1) KR101333627B1 (pt)
CN (1) CN101128469B (pt)
AT (1) ATE440848T1 (pt)
AU (1) AU2006217922B2 (pt)
BR (1) BRPI0607827B8 (pt)
CA (1) CA2595295C (pt)
DE (1) DE602006008751D1 (pt)
DK (1) DK1856125T3 (pt)
ES (1) ES2331257T3 (pt)
IL (1) IL184519A (pt)
MX (1) MX2007010378A (pt)
NO (1) NO20074880L (pt)
PL (1) PL1856125T3 (pt)
PT (1) PT1856125E (pt)
RU (1) RU2421459C2 (pt)
WO (1) WO2006089942A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5288153B2 (ja) * 2007-03-30 2013-09-11 日油株式会社 糖アルコール誘導体およびアルケニル基含有糖アルコール誘導体の製造方法
US8802724B2 (en) * 2010-11-30 2014-08-12 Purdue Research Foundation Processes and intermediates for preparing substituted hexahydrofuro [2,3-b] furans
CN116102569B (zh) * 2021-11-11 2025-02-18 深圳容金科技有限公司 一种展青霉素半抗原的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4776775B2 (ja) 1998-06-23 2011-09-21 アメリカ合衆国 Ｈｉｖ感染哺乳動物を治療するための医薬組成物
WO1999067254A2 (en) 1998-06-23 1999-12-29 The United States Of America Represented By The Secretary, Department Of Health And Human Services Multi-drug resistant retroviral protease inhibitors and use thereof
EP1089328A1 (en) * 1999-09-29 2001-04-04 Infineon Technologies AG Method for manufacturing of a semiconductor device
WO2001025240A1 (en) 1999-10-06 2001-04-12 Tibotec Pharmaceuticals Ltd. HEXAHYDROFURO'2,3-B!FURAN-3-YL-N- {3'(1,3-BENZODIOXOL -5- YLSULFONYL) (ISOBUTYL) AMINO! -1-BENZYL-2-HYDROXYPROPYL} CARBAMATE AS RETROVIRAL PROTEASE INHIBITOR
BR0207862A (pt) 2001-02-14 2004-06-22 Tibotec Pharm Ltd Inibidores de protease de hiv 2-(amino-substituìda)-benzotiazol-sulfonamida de amplo espectro
OA12464A (en) 2001-04-09 2006-05-24 Tibotec Pharm Ltd Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide HIV protease inhibitors.
EE05307B1 (et) 2001-05-11 2010-06-15 Tibotec Pharmaceuticals Ltd. Laiaspektrilised 2-aminobensoksasoolsulfoonamiidid kui HIV proteaasi inhibiitorid, nende kasutamine, farmatseutiline kompositsioon ja meetod retroviiruse replikatsiooni inhibeerimiseks
US7087373B2 (en) 2001-06-05 2006-08-08 Tibotec Pharmaceuticals Ltd. Methods for determining plasma free drug concentration by direct measurement of binding affinity of protease inhibitors to plasma proteins
AR037797A1 (es) 2001-12-12 2004-12-01 Tibotec Pharm Ltd Combinacion de inhibidores de proteasa dependientes del citocromo p450
CN100448444C (zh) 2001-12-21 2009-01-07 泰博特克药品有限公司 含杂环取代苯基的磺酰胺广谱hiv蛋白酶抑制剂
US20040009890A1 (en) 2002-01-07 2004-01-15 Erickson John W. Broad spectrum inhibitors
JP2005517454A (ja) 2002-02-22 2005-06-16 テイボテク・ビーブイビーエイ 抗レトロウイルス活性に対するヒト血漿もしくは血清タンパク質の結合の影響の決定方法
US7157489B2 (en) 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
MY142238A (en) 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
AU2003231765B9 (en) 2002-04-26 2010-01-28 Gilead Sciences, Inc. Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds and the compounds as such
ES2503551T5 (es) 2002-05-16 2021-10-28 Janssen Sciences Ireland Unlimited Co Formas pseudopolimórficas de un inhibidor de la proteasa de VIH
ATE371652T1 (de) 2002-05-17 2007-09-15 Tibotec Pharm Ltd Substituierte benzisoxazolsulfonamide mit breitbändiger hiv-protease hemmender wirkung
US7217506B2 (en) 2002-07-01 2007-05-15 Tibotec Pharmaceuticals, Ltd. Mutational profiles in HIV-1 protease correlated with phenotypic protease inhibitor resistance

Also Published As

Publication number Publication date
EP1856125B1 (en) 2009-08-26
CN101128469B (zh) 2012-11-14
ATE440848T1 (de) 2009-09-15
JP2008531522A (ja) 2008-08-14
CA2595295C (en) 2014-07-08
EP1856125A1 (en) 2007-11-21
DK1856125T3 (da) 2009-12-07
RU2007135345A (ru) 2009-03-27
BRPI0607827B8 (pt) 2021-05-25
CA2595295A1 (en) 2006-08-31
US20120041215A1 (en) 2012-02-16
IL184519A0 (en) 2007-10-31
WO2006089942A8 (en) 2007-12-13
DE602006008751D1 (de) 2009-10-08
MX2007010378A (es) 2007-09-25
AU2006217922B2 (en) 2012-04-05
JP5260965B2 (ja) 2013-08-14
CN101128469A (zh) 2008-02-20
KR101333627B1 (ko) 2013-11-27
PT1856125E (pt) 2009-11-06
US8183394B2 (en) 2012-05-22
NO20074880L (no) 2007-09-25
PL1856125T3 (pl) 2010-01-29
US20090054668A1 (en) 2009-02-26
WO2006089942A1 (en) 2006-08-31
US8067463B2 (en) 2011-11-29
BRPI0607827B1 (pt) 2019-11-05
RU2421459C2 (ru) 2011-06-20
IL184519A (en) 2012-01-31
ES2331257T3 (es) 2009-12-28
AU2006217922A1 (en) 2006-08-31
KR20080005183A (ko) 2008-01-10

Similar Documents

Publication Publication Date Title
CR7970S (es) Botella
BRPI0615029A2 (pt) processos e intermediários
BRPI0812712A2 (pt) produto, processo para produzir o produto, e, uso do produto
UA97126C2 (ru) Процесс шлифования сапфирной основы
DE602007011235D1 (de) Eckstück für eine matratze sowie matratze und entsprechendes herstellungsverfahren
CR10157A (es) Compuestos químicos
BR0308185B1 (pt) processo para a produÇço de fluidos de hidrocarboneto.
ECSP066637A (es) Biaril sulfonamidas y métodos para su uso
PA8804601A1 (es) 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su producción y su uso como agentes antiinflamatorios.
UY30488A1 (es) Bencilaminas,un proceso para su produccion y su uso como agentes anti-inflamatorios.
BRPI0912163A2 (pt) Composto químico, processo para a produção de um composto, compsição química, e, uso de um composto químico.
BRPI0719706A2 (pt) Processo para a preparação do 1,3-propanodiol.
UY30185A1 (es) Método para la producción preferencial de isómeros geométricos y método de aislamiento
BRPI0519710A2 (pt) aminoÁlcoois tricÍclicos, processo para sua preparaÇço e seu emprego como anti-inflamatàrio
BR0215511B1 (pt) processo para preparar diglicerídeos.
BRPI0608137A2 (pt) processo de epoxidação de olefina, catalisador para uso no processo, carreador para uso na fabricação de catalisador, e processo para fabricar o carreador
BRPI0607827B8 (pt) composto precursor de inibidor de protease, processo para a produção do referido composto e seu uso
BRPI0515186A (pt) derivados de alquilideno-tetrahidronaftaleno, processo para a sua produção e seu uso como antiinflamatório
BRPI0612621B8 (pt) processo para produzir compostos químicos, e, composto
BRPI0608443A2 (pt) processo para a produção de mesclas de polímero, e, uso de mesclas de polímero
BRPI0607390A2 (pt) Processo para recuperar cci-779 de licores mâe
UA94391C2 (ru) Синтез предшественника ингибитора протеазы
BRPI0614362A2 (pt) processo para produzir cercosporamida, cercosporamida, produto farmacêutico, e, microorganismo
DE502005005720D1 (de) Kontinuierliches verfahren für silazanspaltungen
DE602006005949D1 (de) Ummantelung für eine mikrowellenantenne

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TIBOTEC PHARMACEUTICALS (IE)

B25D Requested change of name of applicant approved

Owner name: JANSSEN R AND D IRELAND (IE)

B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/11/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/02/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2711 DE 20-12-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.